RedHill's Opaganib Shows Promise in Neuroblastoma and Triple-Negative Breast Cancer Studies at AACR 2026

Key Takeaways

• Opaganib showed positive effects as add-on therapy in neuroblastoma and triple-negative breast cancer preclinical models
• Independent studies by Penn State University and Apogee Biotechnology demonstrated enhanced chemotherapy efficacy
• Data presented at AACR 2026 supports potential expansion of opaganib’s oncology applications beyond current indications

---

RedHill Biopharma Presents Encouraging Preclinical Data for Opaganib

RedHill Biopharma announced positive preclinical results for opaganib as a potential combination therapy for neuroblastoma and triple-negative breast cancer, with data independently presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

Neuroblastoma Study Results

The neuroblastoma research, conducted by Penn State University’s Jeremy Hengst and Apogee Biotechnology with funding from the Beat Childhood Cancer Foundation and Four Diamonds, indicates that opaganib may enhance the effectiveness of existing chemotherapy regimens. Neuroblastoma represents one of the most common solid tumors in children, with high-risk cases requiring intensive treatment approaches.

Triple-Negative Breast Cancer Findings

Separate preclinical studies demonstrated opaganib’s ability to augment anti-tumor immunity in triple-negative breast cancer models. TNBC accounts for approximately 15% of all breast cancers and is characterized by limited treatment options and aggressive behavior, making new therapeutic approaches particularly valuable.

Market Implications and Development Path

These findings expand opaganib’s potential therapeutic applications beyond its current development programs. The drug, which targets sphingosine kinase-2 (SK2), has previously shown activity in other oncology indications and inflammatory conditions.

The independent nature of these studies, conducted by academic institutions rather than RedHill directly, adds credibility to the findings. However, translation from preclinical models to human clinical trials remains a critical next step.

Investment and Development Considerations

For RedHill Biopharma, these results provide additional validation for opaganib’s mechanism of action across multiple cancer types. The company may consider expanding its clinical development strategy to include pediatric oncology and additional breast cancer indications, pending further preclinical validation and regulatory discussions.

The timing of these presentations at AACR 2026, a premier oncology research conference, positions RedHill to engage with potential collaborators and investors interested in the expanded therapeutic potential of opaganib.

---

Frequently Asked Questions

What does this mean for patients with neuroblastoma or triple-negative breast cancer?

These are early preclinical studies, so opaganib is not yet available for these conditions. Patients should continue following their current treatment plans while researchers work to advance these findings toward clinical trials.

When will opaganib be available for these cancer types?

Clinical trials would need to be conducted before regulatory approval. This process typically takes several years, and there’s no confirmed timeline for opaganib trials in neuroblastoma or triple-negative breast cancer.

How does opaganib compare to existing treatments for these cancers?

The preclinical data suggests opaganib works as an add-on therapy to enhance existing treatments rather than replace them. Its unique mechanism targeting sphingosine kinase-2 may provide complementary benefits to current chemotherapy regimens.